Author: South Centre

Direct Monetary Costs of Intellectual Property for Developing Countries. A Changing Balance for TRIPS?

Posted by | Mar 4, 2022 | , ,

[South Centre] It is startling that almost no discussion exists on the direct monetary costs for countries of the IP international regulatory framework. Indeed, on top of the inherent costs on ´access´ or ´learning´ abilities, there are some important tangible, measurable, direct monetary costs to countries. These costs are the financial payments that occur simply for the use of intellectual property. These payments are relevant in any discussion on the role of IP in the context of development. An overview of some findings is presented in this report, with the aim of promoting an assessment and discussion at the WTO and other fora whenever there is a consideration of the impacts of the IP international regulatory framework, notably the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement) in individual countries.

Read More

Can Negotiations at the World Health Organization Lead to a Just Framework for the Prevention, Preparedness and Response to Pandemics as Global Public Goods?

Posted by | Mar 1, 2022 | ,

[Viviana Muñoz Tellez] This paper advances that WHO Member States, having agreed to the objectives of advancing equity and solidarity for future pandemic prevention, preparedness and response, now must operationalize these. The paper offers suggestions for the ongoing WHO processes of: 1) review of recommendations under examination by the Working Group on Strengthening WHO Preparedness and Response to Health Emergencies, 2) consideration of potential amendments to the International Health Regulations (IHR) 2005, and 3) elaboration of a draft text for an international instrument on pandemic preparedness and response.

Read More

A Review of WTO Disputes on TRIPS: Implications for Use of Flexibilities for Public Health

Posted by | Feb 16, 2022 | ,

[Nirmalya Syam] The use of TRIPS flexibilities by WTO members involves interpretation of the obligations under TRIPS which can be challenged under the WTO dispute settlement system. Mutually agreed solutions, panel or Appellate Body decisions adopted in such disputes can thus impact the scope of TRIPS flexibilities to address, among others, public health objectives. This paper explores how the WTO dispute settlement system applies to disputes under TRIPS, and reviews the outcomes of the disputes relating to the implementation of TRIPS obligations in the context of pharmaceutical products.

Read More

The Right to Health in Pharmaceutical Patent Disputes

Posted by | Feb 9, 2022 |

[Emmanuel Kolawole Oke] This paper examines how the courts in three developing countries (Kenya, South Africa, and India) have addressed the tension between patent rights on pharmaceutical products and the right to health. The paper begins by examining the nature of the relationship between patent rights and the right to health. It thereafter explores the justiciability of the right to health in Kenya, South Africa, and India. Furthermore, the paper provides an analysis of how the courts in these three developing countries have adjudicated some of the pharmaceutical patent cases involving tensions between the right to health and patent rights. The paper contends that by incorporating the right to health into the adjudication of patent disputes, courts in developing countries can play a crucial role in improving access to medicines at affordable prices.

Read More

Mainstreaming Public Health Considerations in Adjudication of Intellectual Property Disputes: Implications of Specialized IP Courts and General Courts

Posted by | Feb 2, 2022 |

[Justice (Retd.) Prabha Sridevan] How can the public interest dimension be considered in the adjudication of intellectual property (IP) disputes, in particular those concerning patents on health technologies such as medicines and vaccines? This is the main question addressed by Justice (Retd.) Prabha Sridevan, former Judge of the Madras High Court and former Chairperson of the Intellectual Property Appellate Board (IPAB) of India, as an expert facilitator, at the Asian Regional Course for Judges on Intellectual Property and Public Health organized by the South Centre in August 2021. Justice Sridevan addressed the pros and cons of adjudication through specialized courts vis-à-vis general courts.

Read More

A TRIPS-COVID Waiver and Overlapping Commitments to Protect Intellectual Property Rights Under International IP and Investment Agreements

Posted by | Jan 27, 2022 | , , ,

[Henning Grosse Ruse-Khan and Federica Paddeu] This paper considers legal implications that are likely to emerge from the implementation of a TRIPS Waiver decision. Assuming that a Waiver is adopted in the form presented in the May 2021 proposal by South Africa and India et al, we review the interaction between the Waiver and other commitments to protect IP rights under international IP and investment treaties. Our principal research question is to analyze whether domestic measures implementing the Waiver are compatible with the implementing State’s other obligations to protect IP rights established under multilateral IP treaties, IP and Investment Chapters of FTAs as well as BITs.

Read More

Vaccines, Medicines and COVID-19: How Can WHO Be Given a Stronger Voice?

Posted by | Jan 10, 2022 | , ,

[Germán Velásquez] The considerable health, economic and social challenge that the world faced in early 2020 with COVID-19 continued and worsened in many parts of the world in the second half of 2020 and into 2021. How can an agency like WHO be given a stronger voice to exercise authority and leadership? This book is a collection of research papers produced by the author between 2020 and early 2021 that helps answer this question. The topics address the state of thinking and debate – particularly with regard to medicines and vaccines – that would enable a response to this pandemic or subsequent crises that may emerge.

Read More

Competition Law and Access to Medicines: Lessons from Brazilian Regulation and Practice

Posted by | Jan 5, 2022 |

[Matheus Z. Falcão, Mariana Gondo and Ana Carolina Navarrete] Competition law may play an important role in drug pricing control by containing high prices derived from economic violations. Since the use of competition tools is not limited by the TRIPS Agreement or other international binding disciplines, there is ample policy room to explore how countries, especially in the Global South, can benefit from strengthening their jurisdiction on that matter.

Read More

Potential Claims related to IP and Public Health in Investment Agreements: COVID-19, the Proposed TRIPS Waiver and Beyond

Posted by | Dec 9, 2021 |

[Cynthia Ho] An under-examined issue during the COVID-19 crisis is the potential liability of countries under investment agreements for taking steps to mitigate COVID issues.  This Policy Brief provides an overview of how countries may be liable to companies for taking domestic action to protect public health, including pre-COVID claims related to Intellectual Property (IP), as well as possible claims because of COVID emergency measures, including claims that could result if the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) Waiver was adopted.  The current COVID-19 crisis opens the opportunity to consider and reevaluate the unnecessary threat of international agreements that allow for investment claims and potentially consider their termination.

Read More

Waive Intelletual Property rights and Save Lives

Posted by | Nov 30, 2021 | ,

[Srividhya Ragavan] In October of 2020, when India and South Africa proposed a waiver from certain provisions of the TRIPS agreement, it was meant to increase local manufacturing capacity in these countries… The waiver has an additional role to play in the larger trade schema. In enabling vaccination of populations across the globe, the waiver would be critical to normalize global trade.

Read More

The Doha Ministerial Declaration on TRIPS and Public Health on its Twentieth Anniversary

Posted by | Nov 24, 2021 |

[Nirmalya Syam, Viviana Munoz, Carlos M. Correa and Vitor Ido] This Policy Brief reviews the role of the Doha Declaration on TRIPS and Public Health in the twenty years since its adoption. It finds that the Doha Declaration has contributed to advance the use of the TRIPS flexibilities to promote public health and should be considered an important subsequent agreement to the TRIPS Agreement, despite the continuing challenges for WTO members to implement the TRIPS flexibilities in full.

Read More

Access to Medicines and Vaccines: Implementing Flexibilities Under Intellectual Property Law

Posted by | Nov 8, 2021 | ,

[Carlos M. Correa and Reto M. Hilty, eds.] This book is an outcome of a partnership between the Max Planck Institute (MPI) for Innovation and Competition and the South Centre, which jointly organized a Global Forum on Intellectual Property, Access to Medicine and Innovation in Munich on 9– 10 December 2019. It examines topics of particular relevance for shaping intellectual property regimes that take into account public health concerns. It provides not only deep analyses but options for the interpretation of existing regulations or the adoption of new legislation that, being consistent with the TRIPS Agreement, can allow the judiciary and policy makers to take such concerns into account. In different chapters, the book addresses various dimensions of the flexibilities allowed under the TRIPS Agreement. Although there is a significant literature and statements on the subject, such as the ‘Declaration on Patent Protection. Regulatory Sovereignty under TRIPS’ elaborated under the auspices of the MPI, the book contains new reflections and examines recent developments in case law and legislation. Click here for more.

Read More

Compulsory licensing vs. the IP waiver: what is the best way to end the COVID-19 pandemic?

Posted by | Oct 29, 2021 | , ,

[Olga Gurgula] This policy brief examines the currently discussed proposals at the World Trade Organization (WTO) that aim to resolve the problem of the production shortages of COVID-19 vaccines. This includes the two key submissions, i.e. the proposal by South Africa and India on the Intellectual Property (IP) waiver, partially supported by the United States (US), and the European Union (EU) proposal to clarify the use of compulsory licensing.

Read More

Call for Abstracts – 20 years of the Doha Declaration on TRIPS and Public Health

Posted by | Oct 12, 2021 | ,

The Doha Declaration on the TRIPS Agreement and Public Health (‘Doha Declaration’) represented a groundbreaking moment in the history of intellectual property (IP) international policy, recognizing that Member States should not be prevented from taking measures to protect public health, reaffirming the right to use the so-called TRIPS flexibilities to that aim, such as compulsory licensing and parallel imports. The impact of IP protection on public health has continued to be at the forefront of debate to ensure equitable and affordable access to medicines and other medical products globally, and especially in the global South. The Covid-19 pandemic brought new challenges. Solutions are being discussed beyond use of TRIPS flexibilities, such as a temporary waiver to TRIPS during the pandemic.

Read More

Strong Intellectual Property Protection, Weak Competition Rules – or the Other Way Around to Accelerate Technology Transfer to the Global South?

Posted by | Sep 27, 2021 |

[Klaus Beiter] Competition law provisions relating to intellectual property (IP) rights should play an enhanced role in facilitating the domestic and international transfer and dissemination of technology. IP-related competition rules in the World Trade Organization (WTO) Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) create an obligation for Member States to apply competition law in the IP context. TRIPS competition rules should be read in a “prodevelopment” fashion – IP rights need to be read reductively, IP-related competition law expansively. Ten considerations for a “prodevelopment” IP-related competition law are formulated.

Read More

Accelerating COVID-19 Vaccine Production via Involuntary Technology Transfer

Posted by | Sep 23, 2021 | ,

[Olga Gurgula] This policy brief explains that the currently discussed proposals at the WTO related to increasing the production of COVID-19 vaccines, including the EU proposal to clarify the use of compulsory licensing and the submission by South Africa and India on the intellectual property (IP) waiver, require complementary mechanisms to rapidly improve the production of COVID-19 vaccines that are urgently needed today.

Read More

Restructuring the Global Vaccine Industry

Posted by | Sep 17, 2021 | ,

[Felix Lobo] The purpose of this report is to analyse the vaccines industry under the focus of Industrial Economics as an input for the design of the pertinent instruments to promote development, manufacturing and distribution of vaccines against SARS-CoV-2 in sufficient amounts to immunize all countries as soon as possible. We also need to be prepared for future emerging infectious diseases with the potential of global expansion.

Read More

The TRIPS COVID-19 Waiver, Challenges for Africa and Decolonizing Intellectual Property

Posted by | Aug 7, 2021 | , , ,

[Yousuf Vawda] The intellectual property (IP) regimes of African countries are a function of their colonial past, which imposed strong protections, and which have been entrenched through the Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS Agreement). This has had a devastating effect on their ability to access necessary health products both before and during the current COVID-19 pandemic. It is important to reflect on the challenges that African countries face, before considering the implications of the WTO TRIPS waiver on COVID-19 (henceforth, waiver). In assessing the challenges faced by these countries, as well as the possibilities of improving access, this paper argues that while the waiver offers the best available solution to overcome the current supply shortages of a range of COVID-19 health products, in the longer term a break from this past—the decolonization of IP regimes—is necessary.

Read More

The WTO TRIPS Waiver Should Help Build Vaccine Manufacturing Capacity in Africa

Posted by | Jul 29, 2021 | , , ,

[Faizel Ismail] The current global health crisis created by the COVID-19 pandemic has re-focused our attention on the inadequacy of the TRIPS agreement and the patent system to address global public health crises. This time, developing countries must ensure that the TRIPS waiver succeeds in creating the impetus for the building of manufacturing capacity in the poorest countries, especially in Africa, for vaccines, pharmaceuticals and other health technologies. This is the only effective way in which African countries can reduce their dependence on imports of essential medicines and build their health security, contributing to the achievement of the sustainable development goals, for the poorest countries.

Read More

Follow

Facebook     Twitter

PIJIP

infojustice.org is  hosted by the Program on Information Justice and Intellectual Property at American University Washington College of Law.

Infojustice Roundup

Archives | Subscribe

Free to Share

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Blog Categories

Coronavirus
Trade Agreements
NAFTA
TPP
ACTA
Domestic Legislation
Domestic Policy & Litigation
Limitations and Exceptions
Creative Commons
Multilateral (WIPO, WTO, UN)
Takedowns
Access to Medicines
Empirical Research

Ahmed Abdel Latif
Alek Tarkowski
Alexander Dent
Allan Rocha de Souza
Andres Guadamuz
Andres Izquierdo
Brandon Butler
Brook Baker
Burcu Kilic
Carolina Botero
Carolina Rossini
Caroline Ncube
Carrie Sager
Celeste Drake
Christophe Geiger
David Levine
Eve Gray
Hafiz Aziz ur Rehman
Heesob Nam
Hong Xue
Jonathan Band
Jorge Contreras
Jimmy Koo
Joana Varon
Joe Karaganis
Krista Maier
Lina Diaz
Leanne O’Donnell
Marcela Palacio Puerta
Matthew Rimmer
Matthew Webb
Michael Carroll
Michael Geist
Michael Palmedo
Michael Smith
Miguel Morachimo
Meredith Jacob
Margot Kaminski
Pedro Mizukami
Peter Maybarduk
Pranesh Prakash
Rashmi Rangnath
Sangeeta Shashikant
Sara Bannerman
Stela Bivol
Sean Flynn
Stephanie Rosenberg
Susan Chalmers
Thiru Balasubramaniam
William Xu
Peter Yu

RSS Comments on:

  • An error has occurred, which probably means the feed is down. Try again later.

RSS Civil Society Documents

  • An error has occurred, which probably means the feed is down. Try again later.

RSS Comments on:

  • An error has occurred, which probably means the feed is down. Try again later.